Publications by authors named "R Morilla"
Article Synopsis
- Pneumocytis jirovecii infection has been linked to respiratory issues in preterm newborns, highlighting the need to study airway mycobiota in this population.
- A study analyzed nasal samples from 26 preterm infants (with and without respiratory distress) and 13 term infants, revealing that 89.7% of newborns had the ascomycota phylum, with Cladosporium being the most common fungus.
- The research is the first of its kind in this area, indicating potential links between fungal presence and prematurity, but emphasizes the need for further studies due to the small sample size.
Objectives: In cystic fibrosis (CF), there is a predisposition to bronchial colonization by potentially pathogenic microorganisms, such as fungi. Our aims were to describe the dynamics of respiratory mycobiota in patients with CF and to evaluate the geographic, age and gender variability in its distribution.
Methods: Cohort study in which 45 patients with CF from four hospitals in three Spanish cities were followed up during a 1-year period, obtaining spontaneous sputum samples every 3 to 6 months.
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended genome-wide association meta-analysis of a well-characterized cohort of 3255 COVID-19 patients with respiratory failure and 12 488 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluated the combined effects of guadecitabine and pembrolizumab on patients with advanced solid tumors, aiming to see if guadecitabine can make tumors more sensitive to pembrolizumab, which targets immune checkpoints.
- - In a phase 1 trial with 34 participants, the recommended dosage was established as guadecitabine 30 mg/m on specific days alongside pembrolizumab; common side effects included neutropenia and fatigue, but there were no treatment-related deaths reported.
- - Preliminary results showed a 7% objective response rate and 37% of patients achieved disease control for 24 weeks or more; notably, a significant reduction in DNA methylation was observed in
The results of the genotypic characterization of are described in lung tissue samples from 41 Cubans who died of AIDS with pneumocystosis between 1995 and 2008. Histological sections of the lung preserved as formalin-fixed and paraffin-embedded tissue were examined. PCR amplification and nucleotide sequencing of the two mitochondrial genes (large and small) of the pathogen allowed verification of a predominance of genotype 3 (85T/248C) of the large mitochondrial gene and genotype 3 (160A/196T) of the small mitochondrial gene over a period of 14 years (1995-2008).
View Article and Find Full Text PDF